Is there a role for the quantification of RRM1 and ERCC1 expression in pancreatic ductal adenocarcinoma? - Wikidata - wikimedia - TriplyDB

Is there a role for the quantification of RRM1 and ERCC1 expression in pancreatic ductal adenocarcinoma?

Is there a role for the quantification of RRM1 and ERCC1 expression in pancreatic ductal adenocarcinoma?

http://www.wikidata.org/entity/Q34205171

about

Recent treatment advances and novel therapies in pancreas cancer: a review.Clinical implications of ribonucleotide reductase subunit M1 in patients with pancreatic cancer who undergo curative resection followed by adjuvant chemotherapy with gemcitabine.Pancreatic biomarkers: could they be the answer?Quantification and expert evaluation of evidence for chemopredictive biomarkers to personalize cancer treatment.PharmGKB summary: gemcitabine pathway Identification and verification of transthyretin as a potential biomarker for pancreatic ductal adenocarcinoma.Drug sensitivity profiling and molecular characteristics of cells from pleural effusions of patients with lung adenocarcinoma.Drug metabolism and pancreatic cancer.New biomarkers and targets in pancreatic cancer and their application to treatment.Do hENT1 and RRM1 predict the clinical benefit of gemcitabine in pancreatic cancer?Precision Medicine and Pancreatic Cancer: A Gemcitabine Pathway Approach.Combination gemcitabine/cisplatin therapy and ERCC1 expression for resected pancreatic adenocarcinoma: Results of a Phase II prospective trial.MiR-608 regulating the expression of ribonucleotide reductase M1 and cytidine deaminase is repressed through induced gemcitabine chemoresistance in pancreatic cancer cells.Effect of ribonucleotide reductase M1 expression on overall survival in patients with pancreatic cancer receiving gemcitabine chemotherapy: A literature-based meta-analysis.Biomarker-Based Therapy in Pancreatic Ductal Adenocarcinoma: An Emerging Reality?

P2860

Q33625168-61410B6F-2800-4E2C-919F-EFC6399F2744 Q33684978-D7B35D4C-8A7E-457D-9E3F-BA1427E953C0 Q33801371-86AA7D02-759E-47BC-B85D-9EDB8CE49EAD Q33914197-34F6B99C-6A50-4890-ABBE-648F1E7B1561 Q34435450-714F51D7-F7C8-4F2D-9E06-5EA8B4140310 Q34644418-A614A98A-A6BA-4202-AC06-30B14C50A945 Q35591895-26098543-BF0A-4C3A-BF38-161F523957CE Q37542844-7AA3600E-2407-499C-BAEF-5A726EDDB88B Q38021692-C741F521-0E5E-48E0-84B3-C56E5D7CE578 Q38125770-699A6666-335B-4FC2-87D7-3F7C1AE8585B Q39283216-1ECF9A4C-FAAE-4C60-8A14-4FD6B6A24820 Q40631094-CB5CC8B3-B198-450B-8AF6-708C3524584B Q47830761-F2CA4CF2-4B19-471F-BF23-D9141A8968ED Q50040885-F3AD19FA-5246-46FB-830C-F4DA0098B709 Q52739894-CE815889-9126-4AE5-947F-901DFBFB5933

P2860

Is there a role for the quantification of RRM1 and ERCC1 expression in pancreatic ductal adenocarcinoma?

http://www.wikidata.org/entity/Q34205171

description

2012 nî lūn-bûn

@nan

2012 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի մարտին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Is there a role for the quanti ...... creatic ductal adenocarcinoma?

@ast

Is there a role for the quanti ...... creatic ductal adenocarcinoma?

@en

Is there a role for the quanti ...... creatic ductal adenocarcinoma?

@nl

type

label

Is there a role for the quanti ...... creatic ductal adenocarcinoma?

@ast

Is there a role for the quanti ...... creatic ductal adenocarcinoma?

@en

Is there a role for the quanti ...... creatic ductal adenocarcinoma?

@nl

prefLabel

Is there a role for the quanti ...... creatic ductal adenocarcinoma?

@ast

Is there a role for the quanti ...... creatic ductal adenocarcinoma?

@en

Is there a role for the quanti ...... creatic ductal adenocarcinoma?

@nl

P1433

Q34205171-7FA06DBB-0AD7-4BE9-AA7D-56BEB309761C

P1476

Q34205171-404D6F73-7A5E-4961-A9D4-6095E77146A4

P2093

Q34205171-120FA610-EE4F-470C-A1E1-539A0BD7A101

Q34205171-304178D1-02A4-4334-B13E-8F8FD91E30CD

Q34205171-4C4A0DC2-2D02-40BE-9A98-BAFE7A1390D2

Q34205171-567CF724-BA33-4EC0-B45F-C7AE564A1C9A

Q34205171-97AE28D9-86F8-4090-9B5C-D84C46E648D8

Q34205171-BDB348B0-9CC7-4A8E-9DA4-606B325800DC

Q34205171-C4CB6461-692B-4663-964A-1F5AF38C8202

Q34205171-C60C7619-85EB-480B-B6A1-FEEF0342F01B

P2860

Q34205171-03C88814-151E-4A9D-8720-1836E16DFF53

Q34205171-056EE4DF-25C6-4CC6-807B-12F4E1ADCCED

Q34205171-08F84802-18E5-402D-BE9E-6051E9F9CB13

Q34205171-157D584A-1206-4D99-A8AB-7157E5C06EF8

Q34205171-19FBB597-C6B4-42AA-BEF7-FB90BCD42ECA

Q34205171-313775D4-CFA7-4A79-9E2E-CA1FD1A86DFA

Q34205171-317389A4-F984-432D-8D37-F1A9A212C63A

Q34205171-318DECB4-D6FF-48BB-A305-15BAFBD224C2

Q34205171-33D02D1E-2B6D-450B-8590-F76E527CC64A

Q34205171-3E668919-7A33-4317-83A0-B2E7910FEA4A

P2888

Q34205171-7A8B6BEB-4DA9-48ED-9120-9036C9B151A2

P304

Q34205171-26423EBC-1A53-4D15-91C0-839CD4A52566

P31

Q34205171-CA1DC1C1-8A47-457A-BF14-2FCE49CB7FE7

P356

Q34205171-1DA8E89B-AB6A-4827-8A0E-339B0F4F6BC9

P407

Q34205171-A865B1F5-B44C-441D-AC7B-68704849E863

P478

Q34205171-5FEA4447-4857-4DB2-97A5-4B8CB48547EA

P577

Q34205171-A3862A86-2D52-4AB7-8FFB-DE57760EFFE1

P5875

Q34205171-0F729FD0-3CD3-4636-96B5-CAFEBCDE8A80

P6179

Q34205171-2C1BAAF7-F396-47E2-A7D0-E7CD70988D85

P698

Q34205171-E18DF018-DE94-4BE1-ACA8-CBC201F9B23C

P921

Q34205171-1BE4B96D-BDB4-4558-A414-E0D935B7DCF7

P932

Q34205171-D7B28805-DA3A-47DC-91DB-58EBA0C331DF

P356

1471-2407-12-104

P1433

P1476

Is there a role for the quanti ...... creatic ductal adenocarcinoma?

@en

P2093

Agnieszka K Witkiewicz

http://www.w3.org/2001/XMLSchema#string

Benjamin E Leiby

http://www.w3.org/2001/XMLSchema#string

Charles J Yeo

http://www.w3.org/2001/XMLSchema#string

Edward Pequignot

http://www.w3.org/2001/XMLSchema#string

Jonathan R Brody

http://www.w3.org/2001/XMLSchema#string

Matias E Valsecchi

http://www.w3.org/2001/XMLSchema#string

Susan J Littman

http://www.w3.org/2001/XMLSchema#string

Thomas Holdbrook

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer statistics, 2010

pp32 (ANP32A) expression inhibits pancreatic cancer cell growth and induces gemcitabine resistance by disrupting HuR binding to mRNAs

Sequential assembly of the nucleotide excision repair factors in vivo

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells

Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine.

Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer.

Gemcitabine: single-agent and combination therapy in non-small cell lung cancer.

P2888

1471-2407-12-104

P304

104

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2407-12-104

http://www.w3.org/2001/XMLSchema#string

P407

P478

12

http://www.w3.org/2001/XMLSchema#string

P577

2012-03-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221903169

http://www.w3.org/2001/XMLSchema#string

P6179

1007455327

http://www.w3.org/2001/XMLSchema#string

P698

22436573

http://www.w3.org/2001/XMLSchema#string

P921

P932

3364898

http://www.w3.org/2001/XMLSchema#string